tiprankstipranks
Actinium Pharmaceuticals (DE:7AY1)
FRANKFURT:7AY1

Actinium Pharmaceuticals (7AY1) Income Statement

0 Followers

Actinium Pharmaceuticals Income Statement

Last quarter (Q ), Actinium Pharmaceuticals's total revenue was $―, a decrease of ― from the same quarter last year. In Q, Actinium Pharmaceuticals's net income was $-8.67M. See Actinium Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
$ 81.00K$ 81.00K$ 1.03M$ 1.14M$ 0.00$ 0.00
Cost of Revenue
------
Gross Profit
$ 81.00K$ 81.00K$ 1.03M$ 1.14M--
Operating Expense
$ 30.82M$ 52.00M$ 35.13M$ 26.11M$ 22.39M$ 22.07M
Operating Income
$ -49.93M$ -51.92M$ -34.10M$ -24.96M$ -22.39M$ -22.07M
Net Non Operating Interest Income Expense
$ 3.48M$ 3.10M$ 1.09M$ 190.00K$ 178.00K$ 172.00K
Other Income Expense
$ -100.00K$ -100.00K----
Pretax Income
$ -27.34M$ -48.90M$ -33.02M$ -24.77M$ -22.21M$ -21.90M
Tax Provision
$ -1.74M$ -1.74M$ -4.86M$ 373.00K--
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -46.45M$ -48.82M$ -33.02M$ -24.77M$ -22.22M$ -21.90M
Basic EPS
------
Diluted EPS
------
Basic Average Shares
------
Diluted Average Shares
------
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 30.82M$ 52.00M$ 35.13M$ 26.11M$ 22.39M$ 22.07M
Net Income From Continuing And Discontinued Operation
$ -46.45M$ -48.82M$ -33.02M$ -24.77M$ -22.21M$ -21.90M
Normalized Income
$ -23.21M$ -50.64M--$ -22.21M$ -21.90M
Interest Expense
------
EBIT
$ -30.82M$ -52.00M$ -33.02M$ -24.96M$ -22.39M$ -22.07M
EBITDA
$ -30.00M$ -51.21M$ -32.32M$ -24.44M$ -21.95M$ -21.65M
Currency in USD

Actinium Pharmaceuticals Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis